VBY-825

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameVBY-825
Drug Alias NameVBY-106VBY-285VBY-825
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCathepsin S inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitorsCathepsin B inhibitors
TargetsCathepsin SCathepsin BHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsAutoimmune DiseasesNeuralgiaAlzheimer Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVirobay Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVirobay Inc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesNeuralgiaAlzheimer Disease +[4] 

Other Information

ATC CodeN/A
Related LinksN/A